Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 9/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 6/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966013 | 0.81 | PPARD (0.46) | PPARDFFAR1PPARAHSD17B1 | |
| SCHEMBL12798673 | 0.79 | PPARD (0.59) | PPARDPPARAPPARG | |
| SCHEMBL3964811 | 0.78 | FFAR1 (0.63) | PPARDFFAR1PPARAPPARG | |
| SCHEMBL3962243 | 0.77 | PPARD (0.48) | PPARDFFAR1PPARAPPARGHSD17B1 | |
| SCHEMBL16077453 | 0.76 | PPARD (0.53) | PPARDFFAR1PPARAPPARGHSD17B1 | |
| SCHEMBL13284781 | 0.76 | PPARD (0.53) | PPARDFFAR1PPARAPPARGHSD17B1 | |
| SCHEMBL30618514 | 0.76 | CYP1A2 (0.47) | PPARDFFAR1ALDH1A1HSD17B1 | |
| SCHEMBL3348647 | 0.76 | CYP1A2 (0.47) | PPARDFFAR1ALDH1A1HSD17B1 | |
| SCHEMBL820900 | 0.75 | HSD17B1 (0.61) | PPARDFFAR1PPARAMAPTHSD17B1 | |
| SCHEMBL30515129 | 0.75 | HSD17B1 (0.61) | PPARDFFAR1PPARAMAPTHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | PPARD 88/4885FFAR1 111/4885PPARA 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.